Ildong’s chronic hepatitis B treatment ‘Besivo Tab’ become 28th Korean new drug
Ildong Pharmaceutical(CEO Woong-Sup Yoon) acquired approval of ‘Besivo Tab(generic name: besifovir dipivoxil maleat),’ a new chronic hepatitis B treatment developed by on its own, from the Ministry of Health and Welfare.
Thus, ‘Besivo Tab’ not only became the 28th Korean new drug, but will be re...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
